 The U.S. Food and Drug Administration has granted emergency use authorization EUA to Becton Dickinson and Co for a COVID-19 antigen test that can be administered at the point of care and produce results within 15 minutes, the company said on Monday. The FDA has touted the tests as an important tool for combating the pandemic because they can be produced quickly, at relatively low costs, and test patients in a variety of settings. Becton Dickinsons test can be used on its existing BD Veritor System platform, which is employed in about 25,000 healthcare facilities across the United States. 